Marc Stoner
Registered Nurse · Oakdale, CANPI 1801824222
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $981 and has fallen 91.0% since, to $88 in 2025. Among registered nurse clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$475
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$285
- GSK$200
- Lilly USA, LLC$198
- Lundbeck LLC$174
- AbbVie$170
- plus $677 from 14 others
What the payments were for
- Food & beverage$2,16799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $475 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $285 |
| GSK | 15 | $200 |
| Lilly USA, LLC | 10 | $198 |
| Lundbeck LLC | 7 | $174 |
| AbbVie(2 entities) | 9 | $170 |
| Livanova USA, Inc. | 1 | $112 |
| Axsome Therapeutics, Inc. | 4 | $94 |
| Bayer | 4 | $72 |
| Boehringer Ingelheim | 3 | $64 |
| Novo Nordisk | 3 | $58 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Amgen | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Pfizer | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$125
- TEZSPIRE$118
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$112
- AIRSUPRA$103
How this compares
$2,179 in reported general payments places this provider in the 95th percentile of 533 registered nurse providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 43 | $59,490 |
| OzempicSemaglutide | 42 | $35,414 |
| FarxigaDapagliflozin Propanediol | 48 | $25,648 |
| LinzessLinaclotide | 19 | $10,876 |
| JanuviaSitagliptin Phosphate | 15 | $7,591 |
| EliquisApixaban | 12 | $7,557 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $2,906 |
| PremarinEstrogens, Conjugated | 13 | $2,892 |
| PremproEstrogen,con/M-Progest Acet | 12 | $2,566 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,157 |
| Potassium Chloride | 28 | $1,124 |
| ValacyclovirValacyclovir Hcl | 21 | $1,101 |
| Ipratropium Bromide | 43 | $948 |
| Rosuvastatin Calcium | 58 | $769 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 13 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $37 | $59,49043 claims |
| Novo NordiskOzempic | $58 | $35,41442 claims |
| AstraZenecaFarxiga | $475 | $25,64848 claims |
| PfizerEliquis, Premarin, Prempro | $20 | $13,01537 claims |
| AbbVieLinzess | $170 | $10,87619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 533 registered nurse providers in California.
Other registered nurse in Oakdale
- Irina DariychukAntelope$242K
- Sandra DewarLos Angeles$50K
- Naomi GedionLos Angeles$22K
- Nancy WongSan Francisco$14K
- Annie SongOakland$6K
- Ridhima SoftaBakersfield$6K
- Jennifer CorbettOakhurst$5K
- Candice WhealonLos Angeles$5K
- Suzanne FarrarCarlsbad$4K
- Joseph MazzulloBakersfield$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.